3. - Universitätsklinik für FRAUENHEILKUNDE Innsbruck

7.
114
NEWEST Studie
A randomized, open-label, multicenter , phase II study comparing the effects
on proliferation and the efficacy and tolerability of fulvestrant (FASLODEX) 500
mg with fulvestrant (FASLODEX) 250 mg when given as neoadjuvant treatment
in postmenopausal women with estrogen receptor positive breast cancer
Prüfarzt/-ärztin: Prof. Marth, Prof. Taucher, Dr. Egle, Dr. Reimer, OA Hubalek
ATHENA Studie
Avastin Therapy for advanced breast cancer
Open-label study of bevacizumab (AVASTIN) plus taxane monotherapy or in
combination for the first-line treatment of patients with locally recurrent or
metastatic breast cancer
Prüfarzt/-ärztin: Prof. Marth, Prof. Taucher, Dr. Egle, Dr. Reimer, OA Hubalek
Lapatinib Studie
An open-label expanded access study of lapatinib and capecitabine therapy
in subjects with ErbB2 over-expressing locally advanced of metastatic breast
cancer
Prüfarzt/-ärztin: Prof. Marth, Prof. Taucher , Dr. Egle, Dr. Reimer, OA Hubalek
Navelbine oral
Randomized phase II study of the combination of oral vinorelbine with capecitabine
versus a sequential regimen of oral vinorelbine and capecitabine versus
the combination of docetaxel and capecitabine in patients with metastatic
breast cancer previously treated with anthracyclines.
Prüfarzt/-ärztin: Prof. Marth, Prof. Taucher , Dr. Egle, Dr. Reimer, OA Hubalek
Tibolon-Studie
Eine multinationale, multizentrische, randomisierte, doppelblinde,parallele
plazebokontrollierte klinische Studie zur Untersuchung der Sicherheit und
Wirksamkeit von Tibolon (Org OD 14) bei Frauen mit klimakterischen Symptomen
und einer Mammakarzinomanamnese.
Prüfarzt/-ärztin: Prof. Marth, OÄ Ramoni
ABCSG 25
A randomized phase III study comparing biweekly and tailored epirubicin +
cyclophosphamide followed by biweekly tailored docetaxel (dtEC>dtT) (A-Arm)
vs. three weekly epirubicin + cyclophosphamide, 5-Fluorouracil followed by